STOCKS TELEGRAPH

Tag: IGC Stock

  • IGC Pharma, Inc. (IGC) Soars in After Market After Positive Alzheimer’s Research Results

    IGC Pharma, Inc. (NYSE: IGC) witnessed an unprecedented surge in its stock price following the release of encouraging phase 2 results in Alzheimer’s research. The initial uptick of 19.5% during trading hours was just the beginning of an exhilarating journey, as the afterhours session saw an additional 15% spike, propelling the stock beyond its 52-week high.

    Exploring IGC Pharma, Inc.

    Diving into IGC Pharma, Inc.’s niche reveals its commitment to pioneering cannabinoid-based alternative therapies. These innovative treatments target a range of conditions, including Alzheimer’s disease, Parkinson’s disease, and chronic pain.

    Leveraging the synergistic potential of cannabinoids like Tetrahydrocannabinol and Cannabidiol alongside complementary compounds forms the cornerstone of their research strategy, particularly in Alzheimer’s disease.

    Market Response and Anticipation

    The surge in trading volume, quadrupling average levels despite subdued market activity, underscores investors’ growing confidence in the company’s prospects. Speculation is rife that this bullish momentum may carry over into Thursday’s regular trading session, amplifying the excitement surrounding IGC Pharma, Inc.’s trajectory.

    Insights from Phase 2 Trial

    Significant attention is drawn to the recent interim results from the Phase 2 trial evaluating IGC-AD1’s potential in treating Agitation in dementia from Alzheimer’s Disease (AAD). These findings unveiled a tangible reduction in agitation levels compared to the placebo, hinting at a promising therapeutic avenue with IGC-AD1, thus highlighting the significance of this breakthrough.

    Understanding the Market

    Within the broader context, Alzheimer’s disease casts a long shadow, affecting millions of Americans. Of particular note is the often-overlooked Agitation in dementia from Alzheimer’s Disease (AAD), a condition exacerbating cognitive decline and burdening caregivers.

    Existing treatment modalities, fraught with risks, underscore the pressing need for safer and more efficacious alternatives, underscoring the potential significance of IGC-AD1.

    Conclusion

    In summary, the remarkable surge in IGC Pharma, Inc.’s stock price following positive phase 2 results underscores the growing recognition of cannabinoid-based therapies’ potential in addressing complex neurological conditions like AAD.

    As stakeholders await further developments, optimism pervades regarding the company’s trajectory and its ability to deliver treatment to patients in dire need.

  • What Is Driving The India Globalization (IGC) Stock Up In Premarket Session?

    India Globalization Capital Inc. (IGC) stock was up more than 2.6% in pre-market trading at $1.93 at the last check. Last session, IGC stock closed at $1.88, a decrease of -32.86% or -$0.92. During Friday’s session, India Globalization stock fluctuated between $1.86 and $2.38 per share. During the day, shares of the company’s stock exchanged hands in a volume of 23.35 million, exceeding its average daily volume of 9.28 million over the last 50 days and exceeding its YTD average volume of 6.07 million shares.

    IGC stock has gained 235.71% over the past 12 months, and it has gained 33.33% over the past week. India Globalization Capital has gained 21.29 percent over the last six months, and over the past three months, it has gained 17.50 percent. So far this year, IGC shares have returned 20.51%. As a result of news that a treatment patent has been issued, IGC stock is rising.

    In what field did India Globalization Capital have that patent?

    In order to treat conditions such as Alzheimer’s disease and pain, India Globalization Capital, Inc. (IGC) is developing cannabinoid-based therapies. Infrastructure and Life Sciences represent the company’s two main business lines. India Globalization Capital has its headquarters in Potomac, Maryland.

    On July 20, 2021, India Globalization announced that the United States Patent and Trademark Office (“USPTO”) had issued a patent (#11,065,225), announced the company last week.

    • The patent titled “Ultra-Low dose THC as a potential therapeutic and prophylactic agent for Alzheimer’s Disease” was granted to IGC for the treatment of Alzheimer’s disease,
    • The original patent application was filed on August 1, 2016, by the University of South Florida (“USF”).
    • A license was entered into for the patent application and associated research on Alzheimer’s disease between IGC and USF on May 25, 2017.
    • As per the approved patent, India Globalization Capital’s proprietary formulation can be used to treat people who suffer from Alzheimer’s disease.
    • Phase 1 clinical trials for the company’s proprietary formulation, IGC-AD1, have already been announced.

    In its placebo-controlled Multiple Ascending Dose (MAD) phase 1 trial, India Globalization Capital recently announced that Cohort 3 of its IGC-AD1 using THC for patients suffering from Alzheimer’s disease was completed.

    Prospective uses for IGC’s product:

    To For the first time to the best of IGC’s knowledge, low doses of THC, which is a psychoactive member of the cannabinoid class of products produced by the Cannabis sativa plant, have been used to treat Alzheimer’s patients. India Globalization was motivated by the potential that if the proposed clinical trials for IGC-AD1 prove successful, the drug could offer some relief to the estimated 50 million people who are anticipated to be impacted by Alzheimer’s disease by 2030.

  • India Globalization Capital Inc. (IGC) stock surged in the current trading session; Here’s why this is happening

    In the current trading session, India Globalization Capital Inc. (IGC) stock is racking up the prices of its shares by up to 141.89% to trade at the price of $3.58 at the last check. IGC stock previously closed the session at $1.48. The IGC stock volume traded 138.38 million shares today. In the past year up to datemIGC shares have surged by 154.60% and in the past week moved up by 3.50%. India Globalization Capital Inc. is currently valued in the market at $61.09 million and has 45.11 million outstanding shares.

    An overview of India Globalization Capital Inc.

    India Globalization Capital Inc. can be labeled as a conglomerate that focuses mainly on the purchasing and reselling of physical infrastructure commodities. There are two operational segments of the IGC stock’s business model. These segments include Infrastructure Business and Life Sciences. The company is involved in the trading of infrastructure commodities; buying and selling which includes wooden doors, tiles, steel, and marbles, etc. The infrastructure business segment also includes acquiring and renting heavy construction equipment and undertaking highway construction contracts.

    The Life Sciences segment of the company is currently seeing a trend in cannabinoid-based products and has thus started developing cannabinoid-based items and treatments, like Hyalolex for the treatment of patients from uneasiness, disturbance, dementia, melancholy, and rest issue illnesses. India Globalization Capital also focuses on hemp-based CBD imbued items under the Holief brand name; premium hemp-based CBD mixed natural skin and spa line of items under the Herbo brand name, and premium hemp-based CBD implanted seltzer under the Sunday Seltzer brand. Furthermore, it offers offer exchanging, refining, ringing, and white marking administrations under the Holi Hemp brand; and hemp rough concentrates, hemp detaches, and hemp distillates

    The conglomerate has expanded its operations in United States, India, Colombia, and Hong Kong. IGC stock was originated in 2005 and the company is based in Potomac, Maryland.

    Development of IGC’s THC based Alzheimer treatment and its patency

    The IGC stock is keeping up with the trends and growth in the marijuana and cannabis market as more and more states and countries ease down the criminalization law of cannabis. Furthermore, the company has also tapped into the medicinal marijuana and cannabis market which is fairly more legalized than recreational marijuana usage. IGC stock announced on 20th July 2021, that USPTO which stands for United States Patent and Trademark Office has issued a patent for the company’s proprietary development of Alzheimer’s treatment. This treatment is based on the THC dosage which acts as a potential therapeutic and prophylactic agent for the treatment of Alzheimer’s disease.

    The Company as of late reported the fulfillment of Cohort 3 in its fake treatment controlled Multiple Ascending Dose (MAD) stage 1 preliminary for setting up safety and potency of IGC-AD1 that utilizes THC on patients experiencing Alzheimer’s sickness.

    The unique patent application was started by the University of South Florida (“USF”) and documented on August 1, 2016. On May 25, 2017, IGC went into a selective permit concurrence (ELA) with USF concerning the patent application and the related examination led on Alzheimer’s infection.

  • Why India Globalization Capital, Inc (IGC) stock rallied in the after-hours on Wednesday after the recent announcement?

    India Globalization Capital Inc. (IGC) shares rallied 52.03% in after-hours on Wednesday, June 23, 2021, and closed the day at $2.25 per share. in the morning session on Wednesday, IGC’s stock remained unchanged and closed the session at $1.48 per share. IGC shares have risen 153.95% over the last 12 months, and they have moved down 6.92% in the past week. Over the past three months, the stock has lost 13.95%, while over the past six months, it has declined 16.38%.

    Let’s try to find out the reason behind its surge in the after-hours on Wednesday.

    Completion of phase 1 clinical trial of IGC-AD1on Alzheimer’s Patients

    On June 23, 2021, India Globalization Capital, Inc completed Cohort 3 of its Phase 1 clinical trial on IGC’s tetrahydrocannabinol (THC)-based investigational new drug, IGC-AD1, intended to ease the symptoms of individuals suffering from Alzheimer’s disease.

    FDA provided the approval for Phase 1 trial of IGC-AD1, on Alzheimer’s patients on July 30, 2020. On June 8, 2021, IGC completed Cohort 2 of its Phase 1 clinical trial of IGC-AD1.

    The Data and Safety Monitoring Committee of IGC’s clinical trial will review the data from Cohort 3, and IGC will report its findings from all three Cohorts to the FDA.

    Recent financial results announcement

    On June 14, 2021, India Globalization Capital, Inc. released its financial results for the Fiscal Year Ended March 31, 2021.

    FY 2021 financial highlights

    • India Globalization Capital reported revenue of approximately $898 thousand for FY 2021 compared to $4.1 million for Fiscal 2020.
    • Selling, general and administrative expenses were approximately 7.9 million in FY 2021 compared to approximately $6 million for Fiscal 2020.
    • Research and Development expenses were approximately $929 thousand for FY 2021 compared to approximately $1 million for Fiscal 2020.
    • The company suffered a net loss of approximately $8.8 million or $0.21 per share in FY 2021 compared to approximately $7.3 million or $0.19 per share for Fiscal 2020.
    • The company had total assets valued at $23.51 million on March 31, 2021, compared to $17.76 million on March 31, 2020.

    Q3 2021 financial results

    On February 12, 2021, India Globalization Capital, Inc released its financial results for the quarter ended December 31, 2020, which is the third quarter of its 2021 fiscal year.

    The company earned a revenue of $108 thousand for Q3 2021 compared to $573 thousand for Q3 2020.

    Selling, general and administrative expenses were $2,186 thousand for the three months ended December 31, 2020, compared to $1,413 thousand in Q3 2020.

    The company suffered a net comprehensive loss of approximately $2,283 thousand or $0.06 per share in Q3 2021 compared to approximately $1,646 thousand or $0.04 per share for the September 2019 quarter.

    Conclusion

    The IGC stock skyrocketed after the company announced the completion of Cohort 3 of its Phase 1 clinical trial which is positive news and we can expect that IGC stock can further go up in the coming days.

  • 41 Stocks Making Sharp Moves in Pre Market Session

    41 Stocks Making Sharp Moves in Pre Market Session

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading down -4.55% at $1.05 at the time of writing after announcing $6.0 million private placement. Company’s 52-week ranged between $0.54 to $3.50.
    Merrimack Pharmaceuticals Inc. (MACK) stock plunged -6.93% to $6.04 in the pre-market trading. The most recent rating by JP Morgan, on October 07, 2016, is a Neutral.
    Curis Inc. (CRIS) is down more than -5.85% at $1.77 in pre-market hours Thursday December 03, 2020 after declaring that it will host Virtual Event to discuss CA-4948 clinical data. The stock had jumped over 22.88% to $1.88 in the last trading session.
    Before the trading started on December 03, 2020, Obalon Therapeutics Inc. (OBLN) is down -8.62% to reach $1.06. It has been trading in a 52-week range of $0.62 to $2.14.
    Artelo Biosciences Inc. (ARTL) grew over 7.53% at $0.7065 in pre-market trading today following announcement its appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors.
    Acorda Therapeutics Inc. (ACOR), a Biotechnology company, dropped about -3.54% at $0.79 in pre-market trading Thursday.
    Ampio Pharmaceuticals Inc. (AMPE) is up more than 6.8% at $1.1 in pre-market hours Thursday December 03, 2020 after declaring its phase I study for Inhaled Ampion advances to completing enrollment of COVID-19 patients with respiratory distress. The stock had jumped over 12.65% to $1.03 in the last trading session.
    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -6.11% at $0.446 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.
    OrganiGram Holdings Inc. (OGI) stock moved down -2.86 percent to $1.36 in the pre-market trading. The company recently released fourth quarter 2020 results.
    InVivo Therapeutics Holdings Corp. (NVIV) gained over 14.27% at $0.7999 in pre-market trading Thursday December 03, 2020.
    HEXO Corp. (HEXO) lost over -5.98% at $1.1 in pre-market trading Thursday December 03, 2020 as the firm recently revealed that it has repositioned the UP Cannabis brand with a differentiator of 20% THC or higher in all dried flower products, every time.
    Before the trading started on December 03, 2020, Aurora Cannabis Inc. (ACB) is down -2.92% to reach $10.63. It has been trading in a 52-week range of $3.71 to $32.88.
    Before the trading started on December 03, 2020, Golar LNG Limited (GLNG) is down -6.67% to reach $8.75 after declaring that it intends to offer, issue and sell to the public 11,000,000 common shares, par value $1.00 per share, through an underwritten public offering. It has been trading in a 52-week range of $4.54 to $15.24.
    Aeterna Zentaris Inc. (AEZS) stock soared 3.1% to $0.455 in the pre-market trading. The most recent rating by Maxim Group, on July 19, 2017, is a Buy.
    Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) shares are trading up 9.23% at $4.26 at the time of writing after reporting that it has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH). Company’s 52-week ranged between $2.40 to $6.05. Analysts have a consensus price target of $5.50.
    Ashford Hospitality Trust Inc. (AHT), a REIT – Hotel & Motel company, rose about 7.36% at $2.48 in pre-market trading Thursday.
    Ideanomics Inc. (IDEX) grew over 0.86% at $2.35 in pre-market trading today. The technology firm lately declared that its subsidiary, Tree Technologies Sd. Bhd., which owns the Treeletrik brand, has hired Richard Teoh as its Chief Financial Officer.
    AIkido Pharma Inc. (AIKI) is down more than -2.2% at $0.59 in pre-market hours Thursday December 03, 2020. The stock had jumped over 8.94% to $0.60 in the last trading session.
    NIO Limited (NIO), a Auto Manufacturers company, dropped about -2.21% at $46.92 in pre-market trading Thursday after providing its November 2020 delivery results.
    Genius Brands International Inc. (GNUS) is up more than 2.14% at $1.43 in pre-market hours Thursday December 03, 2020. The stock had jumped over 5.26% to $1.40 in the last trading session.
    Micro Focus International plc (MFGP) gained over 2.81% at $5.12 in pre-market trading Thursday December 03, 2020 following the publication its findings of ‘Endless Modernization’ research with Standish Group.
    Trine Acquisition Corp. (NYSE: TRNE) shares are trading up 6.44% at $14.22 at the time of writing. Company’s 52-week ranged between $9.40 to $13.94.
    Before the trading started on December 03, 2020, Borr Drilling Limited (BORR) is down -6.29% to reach $0.7625. The firm recently declared unaudited results for the three and nine months ended September 30, 2020. It has been trading in a 52-week range of $0.24 to $9.12.
    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -2.83% at $22.35 in pre-market trading Thursday.
    Boxlight Corporation (BOXL) lost over -2.53% at $1.54 in pre-market trading Thursday December 03, 2020. An education technology firm recently reported that Shaun Marklew has been appointed as Chief Technology Officer and Patrick Foley will be appointed as Chief Financial Officer on January 16, 2021.
    Before the trading started on December 03, 2020, Pyxis Tankers Inc. (PXS) is up 10.87% to reach $1.02. It has been trading in a 52-week range of $0.62 to $1.37.
    Orbital Energy Group Inc. (OEG) is down more than -3.1% at $1.25 in pre-market hours Thursday December 03, 2020 following announcement its wholly-owned transmission & distribution division, Orbital Power Services signed a Master Services Agreement with a midwestern investor-owned utility.
    Telefonica S.A. (TEF) is down more than -2.64% at $4.43 in pre-market hours Thursday December 03, 2020. The stock had jumped over 1.56% to $4.55 in the last trading session.
    Longview Acquisition Corp. (NYSE: LGVW) shares are trading up 7.86% at $15.79 at the time of writing. Company’s 52-week ranged between $9.34 to $17.99.
    UP Fintech Holding Limited (NASDAQ: TIGR) shares are trading up 3.51% at $5.61 at the time of writing. Company’s 52-week ranged between $2.03 to $7.60.
    Veru Inc. (VERU) gained over 10.39% at $3.4 in pre-market trading Thursday December 03, 2020.
    Tonix Pharmaceuticals Holding Corp. (TNXP) grew over 2.46% at $0.6414 in pre-market trading today.
    Before the trading started on December 03, 2020, Orange S.A. (ORAN) is down -5.39% to reach $12.28 after reporting that it plans to launch a conditional voluntary public takeover bid on all the shares of Orange Belgium that it does not yet own. It has been trading in a 52-week range of $9.93 to $16.08.
    Switchback Energy Acquisition Corporation (SBE) gained over 2.27% at $30.17 in pre-market trading Thursday December 03, 2020.
    Nano Dimension Ltd. (NNDM), a Computer Hardware company, rose about 4.69% at $6.7 in pre-market trading Thursday after closing the previously reported registered direct offering of 11,960,160 of the Company’s American Depositary Shares at a price of $5.00 per ADS.
    Harmony Gold Mining Company Limited (HMY) is down more than -2.42% at $4.44 in pre-market hours Thursday December 03, 2020. The stock had dropped over 0.00% to $4.55 in the last trading session.
    Waddell & Reed Financial Inc. (WDR) stock moved up 46.33 percent to $24.89 in the pre-market trading after declaring a merger agreement with Macquarie Asset Management, under which Macquarie would acquire Waddell & Reed Financial, Inc. for $1.7 Billion.
    Limelight Networks Inc. (LLNW) stock plunged -2.78% to $4.2 in the pre-market trading. The most recent rating by Goldman, on November 30, 2020, is a Neutral.
    Before the trading started on December 03, 2020, XP Inc. (XP) is down -1.88% to reach $39.65 after announcing pricing of public follow-on offering. It has been trading in a 52-week range of $15.50 to $52.94.
    CBAK Energy Technology Inc. (NASDAQ: CBAT) shares are trading up 2.75% at $7.1 at the time of writing. Company’s 52-week ranged between $0.36 to $11.40.
    Splunk Inc. (SPLK) tumbled over -20.5% at $163.69 in pre-market trading today as the firm released fiscal third quarter 2021 financial results.

  • 35 stocks making the biggest moves premarket today

    35 stocks making the biggest moves premarket today

    FuelCell Energy Inc. (FCEL) stock soared 4.75% to $10.15 in the pre-market trading. The most recent rating by JP Morgan, on November 19, 2020, is a Neutral.

    SCWorx Corp. (NASDAQ: WORX) shares are trading down -6.76% at $2.07 at the time of writing. Company’s 52-week ranged between $1.00 to $14.88.

    Nano Dimension Ltd. (NNDM) lost over -12.1% at $5.74 in pre-market trading Monday, November 30, 2020, after announcing that it has entered into definitive agreements with investors for the sale of 11,960,160 of the Company’s American Depositary Shares (“ADSs”) at a price of $5.00 per ADS pursuant to a registered direct offering.

    Moderna Inc. (MRNA) is up more than 9.38% at $138.95 in pre-market hours on Monday, November 30, 2020 after the firm today announced that the primary efficacy analysis of the Phase 3 study of mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a vaccine efficacy of 94.1%. The stock had jumped over 16.35% to $127.03 in the last trading session.

    FreightCar America Inc. (NASDAQ: RAIL) shares are trading down -3.99% at $2.65 at the time of writing. Company’s 52-week ranged between $0.73 to $2.87. Analysts have a consensus price target of $4.50.

    Blink Charging Co. (BLNK), a Specialty Retail company, dropped about -3.25% at $27.09 in pre-market trading Monday. The firm recently declared that it has acquired the EV charging operator U-Go Stations, Inc. and its portfolio of 44 DCFC charging locations.

    Zomedica Corp. (ZOM), a Drug Manufacturers – Specialty & Generic company, dropped about -1.12% at $0.1324 in pre-market trading Monday.

    GameStop Corp. (GME) is up more than 4.1% at $16.74 in pre-market hours Monday November 30, 2020 after declaring 2020 cyber week deals. The stock had jumped over 9.02% to $16.08 in the last trading session. GameStop Announces 2020 Cyber Week Deals.

    Riot Blockchain Inc. (RIOT) grew over 8.64% at $6.79 in pre-market trading today.

    Verastem Inc. (VSTM) stock moved up 5.03 percent to $2.09 in the pre-market trading after reporting the initiation of a Phase 2 registration-directed clinical trial of VS-6766, its RAF/MEK inhibitor, and defactinib, its FAK inhibitor, in patients with recurrent low-grade serous ovarian cancer (LGSOC).

    Tuniu Corporation (TOUR) gained over 6.58% at $3.4 in pre-market trading on Monday, November 30, 2020. Before the trading started on November 30, 2020.

    Novavax Inc. (NVAX) is down -8.31% to reach $115.25 after providing an update on its COVID-19 vaccine program. NVX‑CoV2373 is a stable, prefusion protein antigen derived from the genetic sequence of the SARS-CoV-2 coronavirus spike (S) protein and adjuvanted with Novavax’ proprietary Matrix‑M™. It has been trading in a 52-week range of $3.65 to $189.40.

    Occidental Petroleum Corporation (NYSE: OXY) shares are trading down -2.36% at $16.17 at the time of writing. Company’s 52-week ranged between $8.52 to $47.58. Analysts have a consensus price target of $18.

    RMG Acquisition Corp. (RMG) stock soared 6.6% to $18.1 in the pre-market trading. The firm recently revealed that the close of business on Tuesday, December 1, 2020, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the special meeting to be held to consider and approve the previously announced merger with Romeo Systems, Inc., a Delaware corporation.

    Uxin Limited (UXIN) stock soared 2.53% to $1.62 in the pre-market trading. The most recent rating by JP Morgan, on October 23, 2019, is a Neutral.

    ReneSola Ltd (NYSE: SOL) shares are trading up 8.02% at $8.08 at the time of writing. The technology company recently announced the closing of the sale of a portfolio of operating projects located in the United Kingdom to Atmosclear Investments Ltd, an European renewable energy and cleantech private equity group. Company’s 52-week ranged between $0.85 to $5.67. Analysts have a consensus price target of $22.

    Kandi Technologies Group Inc. (KNDI) tumbled over -2.28% at $13.31 in pre-market trading today after CBAK Energy and Kandi Group signed a supply framework agreement.

    Vaxart Inc. (VXRT) is up more than 4.84% at $7.37 in pre-market hours on Monday, November 30, 2020. The stock had jumped over 9.84% to $7.03 in the last trading session. Before the trading started on November 30, 2020.

    Alibaba Group Holding Limited (BABA) is down -2.3% to reach $270.13. The internet retail company has been named a leader in Gartner’s 2020 Magic Quadrant for Cloud Database Management Systems. It has been trading in a 52-week range of $169.95 to $319.32.

    EyePoint Pharmaceuticals Inc. (EYPT) stock soared 1.97% to $0.55 in the pre-market trading. The most recent rating by B. Riley FBR, on April 06, 2020, is a Neutral.

    Canaan Inc. (NASDAQ: CAN) shares are trading down -7.83% at $5.3 at the time of writing after releasing its unaudited financial results for the three months ended September 30, 2020. Company’s 52-week ranged between $1.76 to $8.69.

    Heat Biologics Inc. (NASDAQ: HTBX) shares are trading down -0.88% at $1.13 at the time of writing. Company’s 52-week ranged between $0.19 to $4.30. Analysts have a consensus price target of $4.

    Yunji Inc. (YJ), an Internet Retail company, dropped about -7.35% at $3.53 in pre-market trading Monday. The firm recently declared its unaudited financial results for the third quarter ended September 30, 2020.

    India Globalization Capital Inc. (IGC) gained over 22.63% at $2.33 in pre-market trading Monday November 30, 2020.

    Oramed Pharmaceuticals Inc. (ORMP) stock moved up 38.65 percent to $6.17 in the pre-market trading. The healthcare firm recently reported that it has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D). Before the trading started on November 30, 2020.

    Schlumberger Limited (SLB) is down -2.06% to reach $21.43. It has been trading in a 52-week range of $11.87 to $41.14.

    Ocugen Inc. (OCGN) stock plunged -1.71% to $0.294 in the pre-market trading. The firm recently revealed that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will speak on “The Promise of Cell & Gene Therapies: Regulatory and Reimbursement Roadblocks” at Xconomy’s Xcelerating Life Sciences New York & Philadelphia Virtual Event on December 3 at 10:30 a.m. Before the trading started on November 30, 2020.

    Gold Fields Limited (GFI) is down -2.52% to reach $8.5. It has been trading in a 52-week range of $3.79 to $14.90. Before the trading started on November 30, 2020.

    Marathon Patent Group Inc. (MARA) is up 15.65% to reach $4.95. It has been trading in a 52-week range of $0.35 to $6.05.

    Kingsoft Cloud Holdings Limited (KC) stock soared 5.13% to $43.69 in the pre-market trading after reporting that it will be included in the MSCI China Index, effective after the U.S. market close on November 30, 2020. The most recent rating by Goldman, on June 29, 2020, is a Buy.

    NanoVibronix Inc. (NASDAQ: NAOV) shares are trading up 5.26% at $0.8 at the time of writing. Company’s 52-week ranged between $0.54 to $3.50.

    Waitr Holdings Inc. (WTRH) stock moved down -1.46 percent to $3.38 in the pre-market trading.

    Hennessy Capital Acquisition Corp. IV (HCAC) gained over 9.0% at $13.69 in pre-market trading on Monday, November 30, 2020.

    Trevena Inc. (TRVN) stock plunged -4.67% to $2.45 in the pre-market trading. The most recent rating by Guggenheim, on September 14, 2020, is a Buy.

    Suncor Energy Inc. (NYSE: SU) shares are trading down -0.58% at $17.15 at the time of writing. The firm lately publicized that it, together with the other Syncrude joint venture owners – Imperial Oil Resources Limited, CNOOC Oil Sands Canada, and Sinopec Oil Sands Partnership – have agreed in principle for Suncor to become the operator of the Syncrude project by the end of 2021. Company’s 52-week ranged between $9.60 to $34.56.

  • Stocks to Watch as Hopes of A COVID-19 Vaccine Drive Up Markets

    Stocks to Watch as Hopes of A COVID-19 Vaccine Drive Up Markets

    The stock markets are headed to a good start this morning. Analysts expect that with Russia’s move to approve a vaccine, the west will also move fast to release one. A vaccine surprise now, or in the near future, could send the markets rocketing as it would offer hopes of a full economic reopening.

    As the markets await such news soon, there is increased optimism that one will be available before the end of the year. This coupled with Trump’s executive orders on the economy are likely to support the markets today, and all through the week. As optimism rises, stocks that have good news such as earnings, technical developments, or major partnerships are likely to record major gains in the day. Some of the stocks that are showing potential for major gains in the day are as below:

    India Globalization Capital Inc. [NASDAQ:IGC]

    India Globalization Capital Inc. is a top gainer pre-market and is up by over 50%. This follows the company’s announcement that the FDA had approved its pain treatment. The company stated that its cannabinoid formula was meant for the treatment of muscle pains, neuropathic pain, and chronic pain. Pain management is big business and costs disability programs, and organizations through lost productivity, more than $500 billion annually. The company stated that it was seeking patents for the product, the delivery systems as well as the molecular modifications among other proprietary technologies. Given the impact that this new treatment will have on its bottom-line, the company could a top gainer all through the day.

    Summer Infant Inc. [NASDAQ:SUMR]

    Summer Infant Inc. is another top performer this morning and is up by 29%. These gains come hours after the company announced its financial results for the 2020 financial year. The company reported that net sales in the quarter stood a $38.23 million, a slight drop from the $46.4 million that it reported in Q2 of 2019. The company attributed this to the COVID-19 pandemic that affected retail availability an also created supplier constraints.  The company also reported that it was restructuring to cut on costs stating that G&A costs dropped from $8.1 million in Q1 to $6.7 million. The company also reported that in Q2, it had cash flows of $9.6 million compared to $2.4 million in a similar quarter a year ago.

    Cellular Biomedicine Group Inc. [NASDAQ:CBMG]

    Cellular Biomedicine Group Inc. is gaining pre-market and is up by 35%. This follows the company’s announcement that it had entered into a definitive agreement for a merger that would take it private. Under the deal, shareholders of CBMG will get $19.75 per common stock.